Reumofan Plus Recall Update

The FDA is issuing an updated alert that Reumofan Plus and Reumofan Plus Premium contain undeclared active ingredients found in prescription drugs that should be used only under the supervision of a health care professional.

Earlier in June 1, 2012, the FDA first warned the public about the dangers of these supplements. Since then, the agency has received further reports of fatalities, stroke, severe GI bleeding, dizziness, insomnia, hyperglycemia, problems with liver and kidney functions, as well as corticosteroid withdrawal syndrome.

Reumofan Plus was found to contain diclofenac sodium, a prescription NSAID.  It is being marketed for the treatment of arthritis, muscle pain, osteoporosis, bone cancer, and other conditions. The FDA is still recommending that consumers should not buy or start using these products.

For more information visit http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm306360.htm.